Giving Hope.

From the minute you walk through our door, our focus is on you.

Welcome to
Carolina BioOncology Institute

At Carolina BioOncology Institute we care for the person, and the disease.

OUR HEALTH SERVICES

OUR FOUNDER

John Powderly, MD  CPI

President  |  CEO

Dr. John Powderly attended Georgetown Medical School from 1991-95 and was awarded the Lawrence Dean Scholarship. His 4th year of Med School was spent at National Cancer Institute (NCI) as an internship on the Immunotherapy Service.   From 1995-1999 he attended the University of Texas, at Houston Health Science Center for a combined Medicine/Pediatrics Residency. In 1999-2000 he was appointed faculty at MD Anderson Cancer Center and performed additional immunotherapy research.  His oncology fellowship at University of North Carolina, Chapel Hill from 2000-02 focused on dendritic cell immunotherapy.

OUR TEAM

Carolina BioOncology Institute has gathered a world class team of medical professionals dedicated to furthering the health and welfare of each patient that comes through our doors. For a detailed view of each team member please click the button below.

MEET OUR TEAM

VIEW OUR FACILITIES

CLINICAL TRIALS

Clinical trial participants have the opportunity to receive new research treatments before they are widely available. With Phase 1 clinical trial units at our headquarters in Huntersville, NC, we’re able to enroll patients in the newest, most promising trials, without the need for long-distance travel.

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects with Locally Advanced or Metastatic Solid Tumors

Click here for more information

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects with Advanced Solid Tumors

Click here for more information

A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

Click here for more information

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 (formerly MGA012) in Patients with Advanced Solid Tumors

Click here for more information

A Phase 1/1b Multicenter STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT, IN COMBINATION WITH CPI-444, AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS

Click here for more information

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects with Advanced Malignancies

Click here for more information

A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Metastatic Colorectal Carcinoma.

Click here for more information

A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies.

Click here for more information

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer.

Click here for more information

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies.

Click here for more information

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Gastrointestinal Malignancies.

Click here for more information

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Solid Tumors.

Click here for more information

A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors

A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

A Phase I Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants with Advanced Malignancies

A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 with and without ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors.

Click here for more information

A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors

Click here for more information

TAB004-01 – A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 in Subjects with Advanced Solid Malignancies including Lymphoma

https://clinicaltrials.gov/ct2/show/NCT04137900?term=TAB004-01&draw=1&rank=1 I insert the link and re label- Click here for more information